David Hamilton at VentureBeat has an article on XDx, a molecular diagnostic company focusing on gene expression tests, which just filed for an IPO to raise as much as $87 million. The article lays out the case for gene-expression-based diagnostics, but also notes that so far these tests have "been slow to catch on." The article runs through similar existing tests, and gives a nice snapshot of the XDx business.